HR 938 · 116th Congress 2019–2021, ended

BLOCKING Act of 2019

Latest action · May 2, 2019 Placed on the Union Calendar, Calendar No. 24.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedJan 31, 2019
  2. Passed HouseNot reached
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019 or the BLOCKING Act of 2019

This bill modifies provisions related to market exclusivity for a generic drug.

Currently, the Food and Drug Administration (FDA) awards 180 days of exclusivity on the market to a first applicant to file a qualifying application for market approval of a generic drug. Generally, this exclusivity period begins upon a first applicant's commercial marketing of the drug.

The bill authorizes the FDA to approve a subsequent generic drug application prior to a first applicant's first date of commercial marketing if (1) the subsequent application is ready for full approval, (2) a first applicant's application has been pending for at least 30 months, and (3) the approval of a first applicant's application is not precluded by patent infringement claims asserted against that first applicant.

Cosponsors 16

Members who signed on, in the order they did. Signatures ran from Jan 31, 2019 to May 1, 2019; 1 is an original cosponsor, there from the day it was introduced.

SeatCosponsorSigned on
R-GAEarl L. "Buddy" CarterOriginalJan 31, 2019
D-MNAngie CraigMar 25, 2019
D-CAAnna G. EshooMar 26, 2019
D-MIDebbie DingellMar 26, 2019
D-NJFrank Pallone, Jr.Mar 26, 2019
D-CARaul RuizMar 26, 2019
D-ILBobby L. RushMar 27, 2019
D-CADoris O. MatsuiMar 27, 2019
D-MAJoseph P. Kennedy IIIMar 27, 2019
D-NJJefferson Van DrewMar 29, 2019
D-NYYvette D. ClarkeApr 2, 2019
R-ORGreg WaldenApr 8, 2019
D-ILJanice D. SchakowskyApr 8, 2019
D-UTBen McAdamsApr 10, 2019
D-FLDebbie Mucarsel-PowellApr 29, 2019

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred Jan 31, 2019Markup Apr 3, 2019Reported May 2, 2019
Health Subcommittee
Referred Feb 2, 2019Markup Mar 27, 2019Reported Mar 27, 2019

Actions 9

Everything that happened, newest first.

  1. May 2, 2019Reported by the Committee on Energy and Commerce. H. Rept. 116-46.
  2. May 2, 2019Placed on the Union Calendar, Calendar No. 24.
  3. Apr 3, 2019Committee Consideration and Mark-up Session Held.
  4. Apr 3, 2019Ordered to be Reported by Voice Vote.
  5. Mar 27, 2019Subcommittee Consideration and Mark-up Session Held.
  6. Mar 27, 2019Forwarded by Subcommittee to Full Committee by Voice Vote .
  7. Feb 2, 2019Referred to the Subcommittee on Health.
  8. Jan 31, 2019Introduced in House
  9. Jan 31, 2019Referred to the House Committee on Energy and Commerce.

In the Congressional Record 2

Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.

WhereIn the RecordMembersDate
HouseDebate and remarks H10118Earl L. "Buddy" Carter R-GADec 11, 2019
HouseDebate and remarks H3429Ben McAdams D-UTMay 2, 2019

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Committee report

Congressional Budget Office cost estimate

  1. Apr 30, 2019H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019As ordered reported by the House Committee on Energy and Commerce on April 3, 2019

Constitutional authority

Congress has the power to enact this legislation pursuant to the following: This bill is enacted pursuant to the power granted to Congress under Article I, Section 8, Clause 3 of the United States Constitution.

The sponsor’s statement, as printed in the Congressional Record, vol. 165, no. 20, January 31, 2019, page H1342.

Printed hearings 1

Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.

NumberHearingCommitteeHeld
Serial No. 116-17LOWERING THE COST OF PRESCRIPTION DRUGS: REDUCING BARRIERS TO MARKET COMPETITION252 pagesEnergy and Commerce CommitteeMar 13, 2019

CRS reports 1

Congressional Research Service work that CRS links to this bill or the law it became, newest first.

Cite it 1

Products on other subjects that cite it, usually among other measures.

Related bills 3

Companion bills and other measures the record links to this one.

Titles 5

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval, and for other purposes.
Short Title(s) as Introduced
BLOCKING Act of 2019
Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019
Short Title(s) as Reported to House
BLOCKING Act of 2019
Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 2

Each version as it was printed, newest first.

  1. May 2, 2019Reported in House
  2. Jan 31, 2019Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.